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Anaphylaxis is a life-threatening condition, with at-risk individuals remaining at chronic high risk of recur-
rence. Anaphylaxis is frequently underrecognized and undertreated by healthcare providers. The ﬁrst-line
pharmacologic intervention for anaphylaxis is epinephrine, and guidelines uniformly agree that its prompt
administration is vital to prevent progression, improve patient outcomes, and reduce hospitalizations and
fatalities. Healthcare costs potentially associated with failure to provide epinephrine (hospitalizations and
emergency department visits) generally exceed those of its provision. At-risk patients are prescribed
epinephrine auto-injectors to facilitate timely administration in the event of an anaphylactic episode. Despite
guideline recommendations that patients carry 2 auto-injectors at all times, a signiﬁcant proportion of patients
fail to do so, with cost of medicine cited as one reason for this lack of adherence. With the increase of high-
deductible healthcare plans, patient adherence to recommendations may be further affected by increased
cost sharing. The recognition and classiﬁcation of epinephrine as a preventive medicine by both the US
Preventive Services Task Force and insurers could increase patient access, improve outcomes, and save lives.
 2016 The Author. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).  The American Journal of Medicine (2016)
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United States, affecting more than 50 million Americans and
costing the healthcare system more than $18 billion annu-
ally.1 Individuals in hyperallergic states are at chronic high
risk for the occurrence of acute anaphylactic episodes, and
as many as 49 million individuals are thought to be at risk in
the United States.2 Annual direct costs of anaphylaxis are
estimated at $1.2 billion.2 Anaphylactic episodes are
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0.1016/j.amjmed.2016.07.018rapid in onset and potentially fatal.3-5 Anaphylaxis may
be immunologic (immunoglobulin E mediated or
noneimmunoglobulin E mediated) or nonimmunologic;
both forms are referred to as “anaphylaxis” in this review, in
line with international guidelines and consensus statements.3
Risk factors for anaphylaxis include age,5,6 comorbidities
(eg, asthma7), and certain medications (eg, beta-blockers
and angiotensin-converting enzyme inhibitors).5,6
Anaphylaxis occurs on a continuum and can begin with
relatively minor symptoms before progressing, in an unpre-
dictable manner, to a life-threatening condition.3 The most
common signs and symptoms include changes in the skin (eg,
itching, erythema, pruritus, urticaria, angioedema) and
respiration (including bronchospasm, laryngeal edema,
cough, respiratory arrest); effects on the gastrointestinal,
cardiovascular, and central nervous systems also may be
evident.3,5 Anaphylaxis often is underrecognized by health-
care professionals both in general practice and in emergency
care,6 particularly if cutaneous signs and symptoms are not
present (these are absent in 10%-20% of patients).5ess article under the CC BY-NC-ND license (http://creativecommons.org/
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medical emergency and requires rapid intervention.5,6
Prompt treatment with epinephrine, the only ﬁrst-line
intervention for anaphylaxis, is recommended to prevent
the progression of an anaphylactic episode.4-6,8 For patients
experiencing an anaphylactic event, epinephrine is the onlyCLINICAL SIGNIFICANCE
Anaphylaxis is life threatening, under-
recognized, and undertreated. Prompt
epinephrine administration is integral to
prevent hospitalizations and deaths.
At-risk patients should carry 2
epinephrine auto-injectors, but many fail
to do so.
Adherence to medications decreases
with the increased cost sharing associ-
ated with high-deductible healthcare
plans.
Classiﬁcation of epinephrine auto-
injectors as preventive medicines by the
USPSTF and/or insurers would eliminate
or reduce cost sharing, improving access
and outcomes.medication proven to prevent
hospitalization and fatalities.6
Because the onset of anaphylaxis
symptoms often occurs in the
community setting,3 at-risk pa-
tients should be prescribed
epinephrine auto-injectors to pro-
vide rapid intramuscular adminis-
tration of epinephrine.4,7,9
However, a large number of pa-
tients prescribed epinephrine auto-
injectors do not have access to one
at the time of an allergen expo-
sure, leading to delayed medica-
tion administration and increased
risk of progression to severe
anaphylaxis.10-13
Currently, many high-
deductible healthcare plans
include epinephrine auto-injectors
among those medications to
which the plan’s deductible ap-
plies rather than as a preventive
medicine exempt from cost
sharing. Because high deductibles and high cost sharing,
such as those in high-deductible healthcare plans, may lead
to decreased use of medical care,14-17 the recognition and
classiﬁcation of epinephrine as a preventive medicine could
improve patient access. Recommended preventive services
or medications (ie, those graded A or B by the US Pre-
ventive Services Task Force [USPSTF]) are not subject to
any cost-sharing requirements for the patient, (eg, de-
ductibles, copayments) (as discussed next), as per the Pa-
tient Protection and Affordable Care Act 2010.18 The role of
epinephrine auto-injectors in the prevention of anaphylaxis
progression and their potential classiﬁcation as preventive
by the USPSTF and inclusion on healthcare plan preventive
medication lists are reviewed.ECONOMIC BURDEN OF ANAPHYLAXIS
The reported incidence of anaphylaxis in the United States is
49.8 in 100,000 person-years,19 with a lifetime prevalence
of approximately 1.6% to 5.1%.10 Anaphylaxis represents
an increasing burden on emergency departments and hos-
pitals. One study reported a 2.23% annual increase in
anaphylaxis-related hospitalizations from 1999 to 2009,
reaching 25.1 per million population annually.20 The same
authors calculated that, from 2006 to 2009, the number of
anaphylaxis-related emergency department presentations
without hospital admission ranged from 17,735 to 21,822.20From 1999 to 2009, anaphylaxis-related deaths totaled 2229
(0.69 per million population), with the annual number of
deaths ranging from 186 to 225 (0.63-0.76 per million
population).20 However, healthcare providers frequently
underreport anaphylaxis because of the unexpected nature of
the event, a lack of accurate diagnosis, and a lack of accuratediagnostic coding.4,21,22 This
means that currently reported rates
of anaphylaxis prevalence and
associated mortality are likely to
be underestimates. In addition,
inaccurate coding makes it difﬁ-
cult for payers to accurately
determine the costs of treating
anaphylaxis versus the costs
associated with preventive
measures.22
Of the estimated annual
direct anaphylaxis costs of $1.2
billion, $294 million relates to
epinephrine costs. Indirect expen-
ditures are estimated at $609
million.2 A survey of caregivers of
children with a food allergy esti-
mated direct medical costs
(including emergency department
visits and hospitalizations) to be
higher, at $3.7 billion per year.23
In a review of literature and
healthcare databases, epinephrinecosts amounted to less than 9% of the total direct costs of
treating patients with food allergy and anaphylaxis, whereas
emergency department visits accounted for 20% of direct
costs.24IMPORTANCE OF PROMPT TREATMENT OF
ANAPHYLAXIS
Guidelines and consensus statements emphasize the
importance of prompt initial administration of epinephrine
for the treatment of anaphylaxis.3-8 Some authors have
speciﬁed that epinephrine is indicated in patients with
“impending anaphylaxis”25 or should be administered
“sooner rather than later.”26 Members of the Anaphylaxis
Practice Parameter Workgroup, commissioned by the Joint
Task Force on Practice Parameters, recommend immediate
treatment with epinephrine to prevent symptom progression
and the occurrence of more severe anaphylaxis.7
Delayed epinephrine administration leads to worse out-
comes and fatalities.3,8,27 A UK study found that of all
anaphylaxis fatalities occurring in a 6-year period, only 14%
of the victims had received epinephrine before cardiac ar-
rest.12 In a 14-month US study of fatal or near-fatal food-
induced anaphylaxis in children and adolescents, only 33%
of the patients with a fatal reaction received epinephrine
within 1 hour of allergen exposure, whereas none of the
patients with a near-fatal reaction received epinephrine at
1246 The American Journal of Medicine, Vol 129, No 12, December 2016the ﬁrst sign of symptoms.28 Although 50% of the patients
with a fatal reaction had been previously prescribed
epinephrine auto-injectors, none had them available at the
time of the reaction. In addition to the risk of fatality, failure
to promptly administer epinephrine may increase the like-
lihood of biphasic anaphylaxis, in which symptoms recur
1 to 72 hours (typically within 8-10 hours) after resolution
of the initial symptoms.5INADEQUATE TREATMENT OF ANAPHYLAXIS
Despite clear recommendations for prompt epinephrine
administration, recognition of anaphylaxis is often incon-
sistent and many patients receive inadequate management.
A review of a national database demonstrated that 57% of
anaphylactic episodes are not recognized in the emergency
department,29 whereas another study reports that anaphy-
laxis is underrecognized in both emergency departments and
urgent care centers.30 Overall, this lack of recognition and
management of anaphylaxis means that patients often do not
receive ﬁrst-line epinephrine treatment. For example, in a
study of pediatric patients with food-induced anaphylaxis,
only 61% received epinephrine (either pre- or post-
admission). The median length of emergency department
stay was shorter for those patients who received epinephrine
before admission to the emergency department (3 vs
4 hours, P ¼ .03), and these patients also were less likely to
be hospitalized (17% vs 43%, P <.001).27 Likewise, other
studies in pediatric patients have shown that as few as 33%
to 50% of anaphylactic patients admitted to the emergency
department receive epinephrine.31,32 In a 12-year study of
12.4 million emergency department visits for allergic re-
actions and anaphylaxis, only 50% of patients with the most
severe reactions received epinephrine.33
Instead of receiving ﬁrst-line epinephrine treatment, pa-
tients often were treated with second-line therapies,
including antihistamines and glucocorticoids.27,32,33 How-
ever, these medications only treat the cutaneous symptoms
of anaphylaxis and do not prevent or relieve life-threatening
upper airway obstruction.5 Furthermore, they may require
several hours to take effect, limiting their utility in the early
hours of an anaphylactic episode.5ADHERENCE
Anaphylaxis has a high risk of recurrence (estimated to be
30%-43%),34 and long-term preventive measures are a key
element of patient care. Discharge from the emergency
department represents the transition to long-term manage-
ment, and emergency department practitioners play a pivotal
role in this step.25 Long-term management approaches
initiated at discharge should include patient education,4,7
allergen avoidance,4,7,26 referral to an allergy specialist,26
and the provision of epinephrine auto-injectors.4,5,7,26 Cur-
rent guidelines recommend that at-risk patients carry
2 epinephrine auto-injectors at all times (because anaphy-
lactic episodes can be biphasic, necessitating theadministration of 2 doses of epinephrine).4,7,9 However,
many patients do not have access to an auto-injector at the
time of recurrence. In one survey, 52% of patients who had
previously experienced anaphylaxis had never received a
self-injectable epinephrine prescription, and 60% did not
have an auto-injector available.10 Other authors have cited
even lower ﬁgures, with an observational study reporting
that only 9% to 28% of patients requiring epinephrine auto-
injectors carried one with them.35 In a study of 14,677 pa-
tients in a large health maintenance organization who had
received a prescription for an epinephrine auto-injector, only
11% reﬁlled consistently.11
Medication cost has been shown to play a critical role in
patient nonadherence.36 Cost of a medication and lack of
insurance coverage for a medication are among the most
common reasons cited by patients for failing to ﬁll or reﬁll a
prescription.37 A review of studies analyzing the relation-
ship between patient cost sharing and adherence estimated
that, for each dollar increase in patient copayments, adher-
ence decreases by 0.4%.14 Moreover, reduction in out-of-
pocket expenses has been identiﬁed as a strategy to improve
adherence among patients with chronic conditions.38
This relationship between cost and adherence extends to
anaphylaxis treatment. When allergists were surveyed about
the medication concerns of patients with anaphylaxis, 56%
listed the cost of the epinephrine auto-injector as a patient
concern and 38% cited patient ﬁnancial inability to ﬁll the
prescription for the epinephrine auto-injector as one of the
most frequent reasons why patients fail to carry an auto-
injector with them.39 Furthermore, 78% of allergists sur-
veyed stated that their patients were likely to use an expired
epinephrine auto-injector if they were unable to afford a new
epinephrine auto-injector.39 Claims data also suggest that
ﬁnancial considerations may represent a barrier to
epinephrine auto-injector use in the United States. For
example, abandonment rates of the EpiPen (Mylan, Can-
onsburg, Pa) auto-injector increase in relation to patient
cost; more than 50% of EpiPen prescriptions are abandoned
when patient cost exceeds $300 (Figure).40EPINEPHRINE AUTO-INJECTOR AS A PREVENTIVE
MEDICATION
The US Treasury Department deﬁnes medications as pre-
ventive “when taken by a person who has developed risk
factors for a disease that has not yet manifested itself or not
yet become clinically apparent (ie, asymptomatic) or to
prevent the reoccurrence of a disease from which a person
has recovered.”41 Recommended practices for prevention,
trigger avoidance, and treatment indicate that anaphylaxis is
a chronic condition with occasional, potentially severe
symptom recurrence.21 Patients with allergies have risk
factors for anaphylaxis, including a previous allergic reac-
tion, comorbidities such as asthma, and treatment with
certain medications.7 Furthermore, patients who have
recovered from anaphylaxis are at risk for reappearance of
symptoms in a future episode.7 Preventive anaphylaxis care
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Figure Abandonment rates with increasing patient cost of the EpiPen (Mylan, Canonsburg, Pa)
(October 2014 to October 2015).40
Fromer Anaphylaxis Prevention: Epinephrine Auto-Injector 1247(ie, ﬁlling an epinephrine auto-injector prescription or
visiting an allergist/immunologist) in the year before an
anaphylactic event has been associated with a lower risk of
severe anaphylaxis.42 These data support the classiﬁcation
of epinephrine, the only ﬁrst-line, lifesaving treatment for
anaphylaxis, as a preventive medication.PREVENTIVE MEDICINE AND HIGH-DEDUCTIBLE
HEALTHCARE PLANS
The USPSTF is an independent, volunteer expert panel that
makes evidence-based recommendations on clinical pre-
ventive procedures, services, and therapies.43 Recommen-
dations are updated regularly on the basis of evidence levelTable 1 US Preventive Services Task Force Grade Deﬁnitions44
Grade Deﬁnition
A The USPSTF recommends. High certainty of substantial
net beneﬁt.
B The USPSTF recommends. High certainty of moderate net
beneﬁt or moderate certainty of moderate to substantia
net beneﬁt.
C The USPSTF recommends selectively offering/providing to
individual patients on the basis of professional judgment
and patient preferences. Moderate certainty of small
net beneﬁt.
D The USPSTF recommends against. Moderate or high certainty
of no net beneﬁt or that harms outweigh beneﬁts.
I The USPSTF concludes that current evidence is insufﬁcient
to assess beneﬁts and harms. Evidence is lacking, of poo
quality, or conﬂicting.
USPSTF ¼ US Preventive Services Task Force.and cost:beneﬁt ratio,43 with services being graded A to D
or I accordingly (Table 1).44 The USPSTF recommends that
those services receiving grades A or B should be offered or
provided to patients. Grade A services are those where there
is a high certainty of substantial net beneﬁt, and Grade B
services have either a moderate certainty of moderate or
substantial beneﬁt or a high certainty of moderate beneﬁt
(Table 1).44
Per the Patient Protection and Affordable Care Act
2010,18 the cost of those preventive drugs that are given
USPSTF grade A or B ratings is covered in healthcare in-
surance plans, including in high-deductible healthcare plans.
To grade preventive medications, the USPSTF evaluates all
available peer-reviewed evidence, often including data fromRecommendations
Offer or provide this service.
l
Offer or provide this service.
Offer or provide this service for selected patients
depending on individual circumstances.
Discourage use.
r
Read the clinical considerations section of USPSTF
Recommendation Statement. If the service is offered,
patients should understand the uncertainty about the
balance of beneﬁts and harms.
Table 2 High Deductible Health Plan Raw Formulary Status of EpiPen (Mylan, Canonsburg, Pa) 2-Pak in Health Exchanges* (N ¼ 100)59
Tier 1 (% of Plans) Tier 2 (% of Plans) Tier 3 (% of Plans) Tier 4 (% of Plans) Approved (% of Plans) Not Reimbursed (% of Plans)
1 66 5 1 5 22
*Numbers are based on a search of the publicly available website www.formularylookup.com. Exchanges contain dynamic information and are updated
frequently, so the exact percentages of plans listed here have likely changed since the original search was conducted in July 2015.
1248 The American Journal of Medicine, Vol 129, No 12, December 2016randomized controlled trials. However, in the case of some
preventive medications recommended by the USPSTF
(eg, folic acid for the prevention of neural tube defects), the
evidence base contains only limited numbers of randomized
controlled trials because of the nature of the medication.45 In
the case of epinephrine, which was introduced before the
advent of randomized controlled trials,5 it would be unethical
to assess efﬁcacy in placebo-controlled or comparator ran-
domized controlled trials (ie, it would not be ethical to
withhold epinephrine when it is the only ﬁrst-line medication
and the only medication known to prevent fatalities).46,47
Partial coverage and high copayments are associated with
decreased uptake of preventive services and poorer patient
outcomes.48,49 Therefore, classiﬁcation of medications as
preventive (grades A or B) by the USPSTF and subsequent
exemption from deductibles in healthcare plans, including
high-deductible healthcare plans, would be expected to in-
crease use. In the case of epinephrine auto-injectors, an in-
crease in the number of patients ﬁlling prescriptions should
improve access at the time of an anaphylactic episode and
avoid delay in epinephrine initiation, thereby reducing
hospitalizations, fatalities, and treatment costs.
High-deductible healthcare plan enrollment has
increased each year, covering up to 19.7 million
individuals in the United States in November 2015.50 High-
deductible healthcare plans have high annual deductibles
and out-of-pocket limits. However, high patient cost
sharing is associated with decreased treatment adherence,14
delayed presentation,51 and adverse outcomes, particularly
among low-income patients in high-deductible healthcare
plans.15-17 Insurers offer full coverage of the cost of pre-
ventive medications with USPSTF grade A or B ratings,
and they have latitude to expand their list of preventive
medicines beyond this automatic inclusion, providing that
the medication conforms to the Internal Revenue Service
deﬁnition of a preventive medication. For classiﬁcation as
preventive within a high-deductible healthcare plan policy,
medications must qualify for reimbursement as part of a
health savings account and cannot include those used to
treat an existing illness, injury, or condition.52 In the
absence of a speciﬁc Internal Revenue Serviceedeﬁned
list,41 some high-deductible healthcare plan preventive
medication lists can be broad and may include such med-
ications as heart failure and diabetes medications, asthma
inhalers, blood-thinning agents, and statins.53-55 Preventive
drugs and services have been shown to be cost-effective in
many cases,56 and employers cite increased productivity
and decreased costs among their reasons for providing
preventive services coverage in employee healthcareplans.57 One survey reported that large employers with
health savings accountequaliﬁed high-deductible health-
care plans were particularly likely to use a liberal deﬁnition
of preventive medications, with 57% of high-deductible
healthcare plans covering preventive medications at
100% in 2013, up from 46% in 2012.58INCLUSION OF EPINEPHRINE AUTO-INJECTOR IN
HEALTHCARE PLANS
The evidence presented suggests that the risk of epinephrine
auto-injector prescription abandonment could be diminished
by inclusion of epinephrine auto-injectors in preventive
medication lists. A review of high-deductible healthcare
plans listed under health exchanges in the Managed Markets
Insight and Technology database showed that the EpiPen
2-Pak was classed as a tier 1 to 2 product in 67% of plans,
classed as a tier 3 to 4 product in 6% of plans, “approved” in
5% of plans, and not reimbursed in 22% of plans
(Table 2).59 However, examples of epinephrine auto-
injectors being listed as preventive medications, exempt
from high deductibles, in high-deductible healthcare plans
are limited.55CONCLUSIONS
Allergy is an important and prevalent condition in the
United States, which puts hyperallergic patients at chronic
risk of anaphylaxis. Timely recognition of anaphylactic
episodes and prompt administration of ﬁrst-line epinephrine
are integral to prevent symptom progression, hospitaliza-
tion, and death. But current recognition and treatment of
anaphylaxis are inadequate, with epinephrine administration
frequently delayed or not given as ﬁrst-line medication.
Guidelines recommend that patients carry 2 epinephrine
auto-injectors; however, a signiﬁcant proportion of patients
fail to do so. Overall medication costs are one of the factors
driving this patient nonadherence, as demonstrated in
Figure 1; because a medication’s price (ie, that paid to a
manufacturer) contributes to overall medication costs,
price is also a factor in patient nonadherence. Reduction
of the price, therefore, would be expected to improve
adherence.
Considering the cost of auto-injectors compared with the
costs of emergency department visits and hospitalizations
associated with failure to treat anaphylaxis appropriately,
these ﬁndings suggest preventive treatment of anaphylaxis
with an epinephrine auto-injector would be cost-effective.
Fromer Anaphylaxis Prevention: Epinephrine Auto-Injector 1249Epinephrine auto-injectors are currently included in the
deductibles of many healthcare plans, which, coupled with
the negative impact of high cost sharing, often decreases
patient adherence. With more patients enrolling in high-
deductible healthcare plans, fewer of them may be willing
or able to obtain epinephrine auto-injectors. However, the
classiﬁcation of epinephrine auto-injectors as a grade A or B
preventive medicine by the USPSTF and inclusion on pre-
ventive medication lists could be expected to increase pa-
tient access to ﬁrst-line anaphylaxis treatment, improving
outcomes and decreasing fatalities.
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